EMERYVILLE, Calif. , Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX ), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced its Board of Directors has authorized the repurchase of up to $200 million of the Company's common stock.
The share repurchase program does not have an expiration date and Dynavax currently expects that purchases will be executed within a period of up to one year. "Dynavax maintains a disciplined and thoughtful approach to capital allocation, focused on strategically deploying capital where we believe we can create the greatest value for our shareholders and this new program is aligned with that commitment," said Kelly MacDonald , Chief Financial Officer of Dynavax. "We believe this use of capital will benefit our shareholders while also preserving financial flexibility to make the investments required to deliver on our strategy to maximize the HEPLISAV-B® opportunity, advance our research pipeline, and pursue external opportunities to expand our portfolio with strategically aligned assets.
" The timing and amount of any share repurchases under the share repurchase program will be determined by Dynavax's management at its discretion based on ongoing assessments of the capital needs of the business, the market price of Dynavax's common stock and general market conditions. Share repurchases under the program may be made through a variety of methods, which may include o.
